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Tumor progression is accompanied by an altered
myelopoiesis causing the accumulation of immu-
nosuppressive cells. Here, we showed that miR-
142-3p downregulation promoted macrophage
differentiation and determined the acquisition of
their immunosuppressive function in tumor. Tumor-
released cytokines signaling through gp130, the
common subunit of the interleukin-6 cytokine recep-
tor family, induced the LAP* isoform of C/EBPb tran-
scription factor, promoting macrophage generation.
miR-142-3p downregulated gp130 by canonical
binding to its messenger RNA (mRNA) 3’ UTR and
repressed C/EBPb LAP* by noncanonical binding
to its 5’ mRNA coding sequence. Enforced miR
expression impaired macrophage differentiation
both in vitro and in vivo. Mice constitutively ex-
pressing miR-142-3p in the bone marrow showed a
marked increase in survival following immuno-
therapy with tumor-specific T lymphocytes. By
modulating a specific miR in bone marrow pre-
cursors, we thus demonstrated the feasibility of
altering tumor-induced macrophage differentiation
as a potent tool to improve the efficacy of cancer
immunotherapy.
INTRODUCTION
Under pathological conditions, such as infections or cancer
development, a hematopoiesis subversion occurs, which leads
to the expansion of myeloid cells retaining an immature pheno-
type and sharing a propensity to inhibit T lymphocyte activation1236 Immunity 38, 1236–1249, June 27, 2013 ª2013 Elsevier Inc.(Gabrilovich et al., 2012). Mouse myeloid cells systemically
expanded in tumor-bearing hosts express the markers CD11b
and Gr-1 (Ly-6C and Ly-6G) and have been defined collectively
as myeloid-derived suppressor cells (MDSCs). CD11b+Gr-1+
cells do not possess a suppressive phenotype, which is instead
acquired in cancer hosts when they accumulate in the spleen
and within the tumor mass of tumor-bearing mice (Gallina
et al., 2006; Sica and Bronte, 2007). In addition to their immu-
noregulatory activity, CD11b+Gr-1+ cells have been found to
promote tumor angiogenesis, cell invasion, and metastasis
(Gil-Bernabe´ et al., 2012).
It is increasingly clear that CD11b+Gr-1+ cells comprise
different subsets. Granulocytic MDSCs, with high Gr-1 ex-
pression, are less immunosuppressive than monocytic- and
macrophagic-like MDSCs, which possess an intermediate
and low or negative Gr-1 expression, respectively (Dolcetti
et al., 2010).
Experimental models of autochthonous pancreatic ductal
adenocarcinoma (PDAC) formation in mouse have detailed
progressive waves of myelomonocytic cell recruitment
after initiation of the transforming program driven by the
active oncogenes Kras, with CD11b+Gr-1+ cells being among
the first to be recruited within the developing cancer lesions
(Clark et al., 2007). Moreover, recent data suggest that
Kras oncogene-dependent accrual of myelomonocytic cells is
mandatory for pancreatic intraepithelial neoplasia (PanIN)
initiation and progression. This process involves at least
two cytokines, GM-CSF and interleukin-6 (IL-6), which were
shown to be sufficient to originate immunosuppressive
CD11b+Gr-1+ cells from bone marrow (BM) precursors (Marigo
et al., 2010).
In addition, Kras oncogene-driven inflammation at the PanIN
stage critically relied on GM-CSF for both progression to
PDAC and CD11b+Gr-1+ cell recruitment within the pancreatic
stroma. Moreover, this circuit was essential to alter CD8+ cyto-
toxic T cell immunity, and only the blockade of either GM-CSF
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immunity (Bayne et al., 2012; Pylayeva-Gupta et al., 2012).
Interestingly, recruited CD11b+Gr-1+ cells contribute with
transformed epithelial cells to the local production of the cyto-
kines IL-6 and IL-11 that activate the signal transducer and
activator of transcription factor 3 (STAT3). STAT3, in turn,
induces antiapoptotic and proproliferative genes, fueling tumor
initiation, promotion, and progression (Fukuda et al., 2011;
Lesina et al., 2011).
Recent studies have also unveiled a role for some transcrip-
tion factors (TFs) in regulating the myelomonocytic differentia-
tion and recruitment to either tumor site or secondary lymphoid
organs (Sonda et al., 2011). In particular, the STAT family mem-
bers STAT1 (Kusmartsev and Gabrilovich, 2005), STAT3 (Corzo
et al., 2009), and STAT6 (Munera et al., 2010) have been re-
ported as positive regulators of MDSC expansion and activation.
In addition, CCAAT/enhancer-binding protein b (C/EBPb) regu-
lates MDSC functional properties and subset distribution in
different organs (Marigo et al., 2010). Of note, STAT3 can
directly influence C/EBPb activity (Zhang et al., 2010), adding
another level of complexity to the scenario of tumor-enhanced
myelopoiesis.
In addition to TFs, an aberrant microRNA (miR) expression can
also be associated with tumor-induced myelopoiesis (Liu et al.,
2011, 2012 ; Zhang et al., 2011). MiRs are small noncoding
RNAs regulating gene expression primarily through seed-
matched sites located within the 30 untranslated regions (UTR)
of the target mRNA (Bartel, 2009). However, miRs can also
recognize sites in the 5’UTR or in the coding sequence of the
cognate mRNA, even if these bindings seem to be less effective
than those in the canonical 3’ UTRs (Fang and Rajewsky, 2011;
Tay et al., 2008).
Many biological processes, such as embryonic development,
cell differentiation, and division are influenced by the dynamically
modulated expression of specific miRs (Hatfield et al., 2005;
Miska, 2005). Hematopoiesis represents a finely tuned,multistep
process where miRs can exert a fundamental regulator role
(Baltimore et al., 2008; Chen et al., 2004; Chen and Lodish,
2005). For example, miR-17-5p, miR-20a, miR-106a, miR-150,
miR-10a, and miR-146a have been reported to regulate the
physiological differentiation ofmonocytes, B and T lymphocytes,
helper T cells, and dendritic cells (DCs), respectively (Fontana
et al., 2007; Takahashi et al., 2012 ; Turner et al., 2011 ; Zhou
et al., 2007).
Despite the increasing amount of data on the subject, the
molecular mechanisms explaining how neoplastic cells regulate
the expression and the activity of specific TFs and/or miRs in
myeloid compartment are still poorly defined. Furthermore,
reciprocal interaction between miRs and TFs and specific path-
ways controlling either granulocytic or monocytic differentiation
have not been fully elucidated. Here, we determined the ‘‘miR
signature’’ in tumor-infiltrating myeloid cells (TIMs). Among
differentially expressed miRs, we identified miR-142-3p as
critical for preventing macrophage differentiation during tumor-
induced myelopoiesis, by both canonical and non canonical
modulation of the gp130 and C/EBPb signalling. Moreover,
we demonstrated the potential therapeutic application for
miR-142-3p oligonucleotide as adjuvant tool for adoptive T cell
therapy of cancer.RESULTS
miR-142-3p Is Downregulated in Tumor-Associated
CD11b+ Cells
To identify differentially expressed miRs (DEMs) in TIMs, total
RNA was isolated from either tumor-infiltrating or normal
CD11b+ cells purified from the spleen of healthy mice and was
hybridized on to miR arrays (see Figure S1A available online).
Clustering analysis of samples, based on all considered miR
expression profiles, showed that myeloid cells isolated from
tumor-bearing mice had a distinctive miR signature compared
to control healthy spleens (Figure 1A). Among the miR repertoire,
79 were found to be differentially modulated in tumor-infiltrating
versus normal cells (Figure S1B). In particular, the array analysis
showed miR-142-3p and miR-150 were strongly downregulated
in tumor-infiltrating CD11b+ cells. This finding was further
confirmed by qRT-PCR analysis (Figure S1C).
In order to identify the putative targets of the 79 DEMs, we
performed a combined analysis of miR and gene expression
profiles of the same samples. As supported by expression
data, 238 negative correlations, mainly involving downregulated
miRs, were selected (Figure S1D). Many of the predicted target
genes are known regulatory factors of myeloid cell differentiation
and/or proliferation (Figures S1E and S1F). For example, Nras
alteration was linked to an aberrant GM-CSF signaling, causing
a chronic myelomonocytic leukemia-like phenotype (Wang
et al., 2010). Ptgs2 was associated with myeloid cell recruitment
and/or activity during tumor development (Eruslanov et al.,
2010), whereas E2f3was identified as a TF involved in monocyte
differentiation (Schmeier et al., 2009). In addition, both Dapk1
and Ccne1 expression could be regulated by C/EBPb (Gade
et al., 2008; Gutsch et al., 2011), which modulates tumor-
induced myelopoiesis (Marigo et al., 2010). We thus moved to
investigate the role of miR-142-3p and miR-150 in TIM differen-
tiation and activity during altered myelopoiesis.
miR-142-3p Directs Myeloid Cell-Commitment
In order to assess the role ofmiR-142-3p andmiR-150 inmyeloid
cell commitment, we first generated MDSCs in vitro from bone
marrow cultures, as previously described (Marigo et al., 2010).
Specific miR content was measured every day by qRT-PCR
analysis. These two miRs followed very different kinetics (Fig-
ure 1B): miR-142-3p showed a prominent downregulation in
the early phases of cell commitment, whereas miR-150 had a
linear, but delayed, decrease over time. This time-dependent
miR modulation was differently associated with BM-MDSC
generation. The enforced expression of miR-142-3p in BM
cultures determined a significant decrease of total cell numbers
(data not shown), exerting different effects on various cell sub-
sets. In fact, the expression of miR-142-3p, but not miR-150,
in BM cells mostly impaired CD11b+Gr-1lo-neg cell subset
generation (Figure 1C). The morphological analysis showed
that miR-142-3p overexpressing BM-cultures were mainly
driven towards granulocytic differentiation (Figure 1D).
Cytofluorimetric characterization and qRT-PCR analysis
confirmed that the CD11b+Gr-1lo-neg subset was mainly com-
posed of mature macrophages with enhanced expression of
markers (Figure S1G), and genes (Figure S1H), distinct from
M2-oriented, tumor-associated macrophages (GabrilovichImmunity 38, 1236–1249, June 27, 2013 ª2013 Elsevier Inc. 1237
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In addition, purified CD11b+Gr-1lo-neg cells secreted IL-10 but
not IL-12, analogously toM2-polarizedmacrophages (Figure 1E).
Gene-expression analysis of miR-142-3p overexpressing BM
cultures showed that miR upregulation mostly affected genes
related to M2 polarization (Figure S1I). Collectively, these data
indicated that CD11b+Gr-1lo-neg cells possessed a prevalent
M2-profile, even if the expression of M1-macrophage markers,
such as MARCO and Nos2 (Murray and Wynn, 2011), was also
detected (Figure S1G and S1H).
To characterize further miR role in myeloid cell-commitment,
we additionally stimulated BM-MDSCs expressing either control
(CTRL) or miR-142-3p oligos with M-CSF. miR-142-3p overex-
pressing cells showed a clear reduction in macrophage percent-
age and a significant increase in the granulocytes, whereas
the monocytic subset was only partially affected (Figure 1F;
Figure S1L). Collectively, these data suggest that miR-142-3p
content in BM cells regulates the transition to macrophages.
Of note, miR-142-3p-expressing BM-cells exposed to tumor-
cell conditioned medium (TCCM) showed a comparable impair-
ment in macrophage differentiation (Figure 1G).
miR-142-3p Downregulation Is Required for the
Generation and Activity of Immunosuppressive Cells
Among in vitro generated BM-MDSCs, the CD11b+Gr-1lo-neg
subset is endowedwith the highest immune-suppressive activity
(Dolcetti et al., 2010; Marigo et al., 2010). We thus wondered
whether miR-142-3p expression could control the suppressive
behavior of BM-MDSC cultures. We measured cell division in
antigen-stimulated, CFDA-SE-labeled T lymphocytes cultured
with BM-MDSCs previously transfected with either CTRL
or miR oligos. The enhanced expression of miR-142-3p, but
not miR-150, reduced the immunosuppressive activity of BM-
MDSCs, restoring CD8+ T cell proliferation (Figure 2A). A similar
decrease in the immunosuppressive activity was observed in
miR-142-3p-expressing MDSCs generated by the exposure to
TCCM (Figure S2).
We therefore asked whether forced miR downregulation in
myeloid progenitors could support macrophage generation even
in the presence of granulocytic differentiating stimuli. We isolated
BM-CD11b cells, which are capable of generating all the Gr-1
subsets after cytokine treatment (Figure 2B). We infected these
cells with a lentiviral construct (miR-142-3pT) able to ‘‘sponge’’
endogenous miR-142-3p (the infection efficiency was of 38% ±
5%). After infection, CD11b cells were treated with G-CSF toFigure 1. miR-142-3p Is Downregulated in Tumor-Recruited CD11b+ C
(A) The dendrogram shows samples classification resulting from unsupervised an
either the spleen of healthymice (navy) or from themass of the indicated tumors (b
group are shown.
(B) BM cells were cultured with GM-CSF+IL-6 to generate BM-MDSCs. Total RNA
miR-142-3p and miR-150 content was performed. Data, reported as relative qua
(C and D) BM cells from healthy mice were transfected with either CTRL (scramb
analyzed by flow cytometry and cytochemical stain to evaluate myeloid differen
expressing CD11b and Gr-1 markers (C) are reported, and May-Gru¨nwald-Giem
(E) CD11b+/Gr-1lo/neg cells were sorted from GM-CSF+IL-6 treated-BM cells and
ELISA. For comparison, cytokine levels secreted by either M1- or M2-polarized,
(F) Percentages of monocytes, macrophages, and granulocytes in BM cultures f
(G) BM cells were transfected with either CTRL or miR oligo and cultured in the
In all panels, data are expressed as mean ± SE of three independent experimendrive granulocytic differentiation. miR-142-3p downregulation
determined a significant decrease in the percentage of granulo-
cytes with a concomitant increase in the macrophage number.
The differentiation of monocytes was not affected (Figure 2C).
When cultured with antigen-activated CD8+ T cells, G-CSF-
treated CD11b cells showed a poor immunosuppressive
activity (Figure 2D). Of note, the enforced miR-142-3p downre-
gulation augmented the ability of G-CSF-treated CD11b to
block T lymphocyte proliferation (Figure 2D). Thus, miR-142-3p
downregulation in myeloid precursors represents a pivotal event
for the maturation of immunosuppressive macrophages.
IL6st Is a Direct Target of miR-142-3p, and It Is Involved
in Macrophage Commitment
In order to define the molecular mechanisms by which miR-142-
3p controls macrophage differentiation, we computationally
identified regulated genes, focusing on those involved in
monocyte-macrophage commitment. To evaluate whether miR
directly binds to these predicted targets, we set up a luciferase
reporter assay screening by using plasmids in which the firefly
luciferase open reading frame (ORF) was fused to the 3’ UTR
of these genes. miR-142-3p overexpression caused a reduction
in luciferase activity when transfected with the Il6st, Egr2, Id1,
and Pla2g6 coding plasmids, indicating these genes as direct
miR targets (Figure 3A). Mutations in the predicted seed
sequence allowed us to validate miR-142-3p interaction with
the two genes showing the strongest impairment of luciferase
activity, i.e., Il6st and Egr2. In seed-mutated mRNAs, miR-142-
3p addition did not change luciferase activity (Figure 3B).
Between these two targets,we focusedon Il6stgene, the trans-
membrane chain common to all the receptors for IL-6 cytokine
familymembers, because the activation of IL-6 pathway is known
to regulate physiological and pathological myeloid cell differenti-
ation. To verify gp130 role on tumor-altered myelopoiesis, we
injected MCA203 cells either in wild-type (WT) or in mice bearing
a conditional Il6st gene deletion in hematopoietic cells (Il6st/).
After 4 weeks, BM cells were harvested and cultured in the
presence of TCCM to evaluate myeloid cell differentiation. BM
cells from Il6st/ mice showed a clear reduction in the
percentage of the macrophages, associated to an expansion of
both the granulocytic and monocytic compartment (Figure 3C).
Intriguingly, miR overexpression induced a strong reduction in
the phosphorylated STAT3 protein level (Figure 3D), indicating
that miR-142-3p also influenced STAT3 activation, an event
downstream of the IL6st signaling.ells and Regulates Myeloid Cell Differentiation
alysis of all miR expression data obtained from CD11b+ total RNA isolated from
lue). Data from three arrays hybridizedwith pools of at least threemice per each
was isolated from either fresh or cultured BM-cells (days 1–4) and qRT-PCR for
ntity (R.Q.), are normalized to miR level in fresh BM cells.
le) or miR oligo before GM-CSF+IL-6 treatment. After 96 hours, cultures were
tiation. Representative FACS panels and the relative quantification of subsets
sa staining of cytospins is shown (D).
plated for additional 40 hours. IL-10 and IL-12p70 release was measured by
BM-derived macrophages are shown.
urther stimulated with M-CSF.
presence of TCCM. After 96 hours, cultures were analyzed by FACS.
ts. **p < 0.01; ***p < 0.001. See also Figure S1.
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Figure 2. miR-142-3p Regulates Immune-Suppressive Activity of TIMs
(A) CFDA-SE-labeled CD8+ T cells from pmel-1 mice were stimulated with the specific antigen in the presence of BM-MDSCs expressing either CTRL or miR
oligos. CD8+ T cell proliferation was evaluated as CFDA-SE dilution relative to lymphocyte cultures stimulated in the absence of BM-MDSCs (MLPC).
(B) BM CD11b+ and CD11b cells of healthy mice were treated for 4 days with GM-CSF+IL6 before evaluating CD11b/Gr-1 distribution.
(C) BM-CD11b cells were infected with either CTRL or miR-142-3p capturing (miR-142-3pT) lentiviruses and then cultured in the presence of G-CSF. Per-
centages of granulocytes, monocytes, and macrophages are reported.
(D) CD8+ T lymphocytes were antigen-stimulated and cultured for 3 days in the presence of CD11b BM cells generated as in (B) and (C). Histograms represent
the quantification of CD8+ T cell-proliferation evaluated as CFDA-SE dilution relative to control MLPC.
In all panels, data are expressed as mean ± SE from three independent experiments. *p < 0.05;**p < 0.01; ***p < 0.001. See also Figure S2.
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A reported link exists between Stat3 and Cebpb (Zhang et al.,
2010), which regulates the differentiation of immunosuppressive
TIMs (Marigo et al., 2010). We therefore tested whether Cebpb
could be controlled by miR-142-3p. Cebpb mRNA encodes
three isoforms, with different molecular weight and transcription
activity: two activating proteins, LAP* and LAP, and an inhibitory
isoform, LIP. We evaluated C/EBPb isoform amounts in miR
overexpressing NIH-3T3 cells, and we observed a significant
downregulation exclusively in LAP* (Figure 4A).
During cell differentiation, the activating/inhibitory isoform
ratio dynamically changes to guarantee a specific gene-
transcription pattern (Smink et al., 2009). We detected a sig-
nificant variation in isoform ratio, mainly due to downregulation
of the LAP*, in miR-142-3p overexpressing BM-MDSCs
(Figure 4B). Intriguingly, BM cells driven to granulocytic differen-
tiation treatment showed a strong decrease in LAP* content,1240 Immunity 38, 1236–1249, June 27, 2013 ª2013 Elsevier Inc.whereas macrophage differentiation caused LAP* upregulation
(Figure 4C).
To determine whether C/EBPb isoform ratio was altered by
miR-142-3p through STAT3 activity modulation, we treated BM
cells with GM-CSF and IL-6 in the presence of JSI-124, a specific
STAT-3 phosphorylation inhibitor. As previously reported
(Nefedova et al., 2005), the addition of the inhibitor promoted a
strong DC maturation and a reduction in the macrophage
number (Figure S3). JSI-124-treated BM cells showed a strong
LAP* decrease (Figure 4D), an overall response similar to miR-
142-3p enforced expression (Figure 4B), suggesting a direct
link between STAT3 activation and C/EBPb isoform-ratio
modulation.
We additionally ablated gp130 expression in NIH-3T3 cells by
small hairpin RNA (shRNA) (Figure 4E). In the absence of gp130,
we found a significant decrease of both LAP* and LIP expression
(Figure 4F), suggesting that, in addition to gp130 modulation,
AB
C D
Figure 3. A Direct Target of miR-142-3p, IL6st, Is Involved in Macrophage Commitment
(A and B) HEK293T cells were cotransfected with a plasmid carrying the luciferase ORF fused to WT 3’UTR of the indicated genes and with either CTRL or miR-
142-3p oligos (A). Experiments were additionally performed with a plasmid mutated in the seed sequence of 3’UTR (B). The firefly activity was normalized to the
Renilla activity and the normalized value of CTRL-transfected cells was set as 100.
(C) WT (CTRL) or Il6st/ mice were injected with MCA203 cells. After 4 weeks, BM cells were harvested and further cultured with TCCM. Cultures were
analyzed by flow cytometry. Percentages of granulocytes, monocytes, and macrophages are reported. Data from n= 6 mice per group (from two independent
experiments).
(D) Immunoblot analysis (WB) of STAT3 phosphorylation in miR-142-3p-over-expressing NIH-3T3 cells and the related signal quantification (ratio between
phosphorylated STAT3 (pSTAT3)/nonphosphorylated STAT3). Protein levels were normalized to a-actin signal. The normalized STAT3 ratio in CTRL-transfected
cells was set as 1.
In all panels, data are expressed as mean ± SE from three (or five for luciferase assays) independent experiments. *p <0.05;**p < 0.01; ***p < 0.001.
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mechanisms.
miR-142-3p Directly Regulates the C/EBPb Isoform
Ratio and Is Negatively Regulated by LAP*
Wedetected a significant LAP* downregulation even in HEK293T
cells coexpressing miR-142-3p and Cebpb coding sequence
domain (CDS) (Figure 5A). By using RNAHybrid 2.2 algorithm, a
putative miR-142-3p binding site was identified in the Cebpb
CDS (Figure 5B). Of note, this binding site spans the second
start codon, where a loop structure can be created, regulating
the reciprocal isoform expression (Baldwin et al., 2004). Wespeculated that miR binding, by either modifying or interfering
with the loop generation, could control C/EBPb isoform transla-
tion (Figure 5B).
To validate the hypothesis of a direct miR binding, we trans-
fected HEK293T cells with a plasmid carrying the Cebpb CDS
in frame with the luciferase ORF. The addition of miR-142-3p
significantly reduced the luciferase activity (Figure S4A).
Coherently, miR overexpression did not impact the luciferase
activity in cells expressing a mutated CDS (Figure S4A). Results
were validated by protein blot analysis (compare Figures 5A
and 5C). These data unveiled a direct miR-142-3p-Cebpb
interaction.Immunity 38, 1236–1249, June 27, 2013 ª2013 Elsevier Inc. 1241
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Figure 4. LAP* C/EBPb Expression Is Controlled by miR-142-3p
(A and B)WBof C/EBPb isoform expression in the nuclear fraction (NF) of NIH-3T3 cells (A) or BM-MDSCs (B) expressing either CTRL ormiR-142-3p oligo and the
related signal quantification were reported. Protein levels were normalized to nucleoporin-62 (Np62) signal. The normalized C/EBPb value in CTRL-transfected
cells was set as 100. A.U., arbitrary units.
(C) WB of C/EBPb isoform expression in the NF of BM-cells cultured for 96 hours in the presence of different cytokines (GM-CSF/IL-6, G-CSF or M-CSF) and the
related signal quantification were reported.
(D) BM cells were treated for 4 days with GM-CSF+IL-6 and 0.5 mMJSI-124 or DMSO vehicle were added 24 hours before culture harvesting. C/EBPb expression
was analyzed by WB.
(E) Il6stwas ablated in NIH-3T3 cells by transfecting different shRNAs expressing puromycin resistance. After 4 weeks of antibiotic selection, IL-6 expressionwas
analyzed in whole-cell extract by WB. Silencing efficiency: sh A = 85% sh C = 10%.
(F) WB for C/EBPb isoform expression in the NF of Il6st-silenced NIH-3T3 cells and the relative signal quantification were reported.
In all panels, data are expressed as mean ± SE of three independent experiments. *p < 0.05 **p < 0.01 ***p < 0.001. See also Figure S3.
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whether C/EBPb could in turn regulate miR-142-3p expression.
A plasmid coding a region of 1,250 bp upstream of the pri-
miR-142-3p sequence (named Walk 1) fused to the luciferase
ORF was generated. This region contains the miR promoter
and nine computationally identified C/EBPb binding sites. In
addition, two shorter constructs (Walk 2 andWalk 3; Figure S4B)
were considered. Moreover, to further dissect the role of each
isoform in miR regulation, Cebpb sequence was modified to
generate a LAP*-coding construct (Figures S4C and S4D). No
miR-142-3p promoter activation was observed when cells
were cotransfected with miR promoter plasmids and LAP*
coding construct (Figure 5D). On the other hand, a clear incre-1242 Immunity 38, 1236–1249, June 27, 2013 ª2013 Elsevier Inc.ment in luciferase activity was detected by transfecting cells
with a LIP-coding plasmid. The reduction in miR promoter activ-
ity linearly correlated with the binding site number (Figure 5D).
To evaluate the impact of C/EBPb isoform ratio on miR
promoter activity, we cotransfected HEK293T with different
concentrations of LAP*- and LIP-coding plasmids. We found
that an increased ratio caused a linear promoter activity reduc-
tion (Figure 5E), whereas a higher promoter activity was
observed when the ratio decreased (Figure 5F).
In summary, we hypothesize that during tumor-induced
myelopoiesis a mini-circuit is activated by tumor-released IL-6
family cytokines. Their binding to the IL-6 subunit determines
both a STAT3-mediated and a direct C/EBPb isoform ratio
A B
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Figure 5. miR-142-3p Directly Regulates the C/EBPb Isoform Ratio and Is Negatively Regulated by LAP*
(A) Signal quantification of C/EBPb isoform expression by WB in the NF of HEK293T cells transfected with mouse C/EBPb CDS and either CTRL or miR-142-3p
oligo.
(B) Computationally predictedmiR-142-3p binding site in the C/EBPbCDS (left) and the hypothesized impact ofmiR binding on AUG recognition (right). Blue/grey
arrow = active/not active start codons, respectively.
(C) Signal quantification of C/EBPb expression by WB in HEK293T cells transfected with a plasmid coding a mutated C/EBPb CDS and with either CTRL or
miR-142-3p oligos.
(D) Luciferase assay in HEK293T cells transfected with constructs expressing three putative miR-142-3p promoter sequences (Walk 1, 2, and 3), and
plasmids expressing either the LIP or the LAP* isoforms. Luciferase activity was normalized to the Renilla luciferase activity and the normalized value of
pcDNA3.1-trasfected cells was set as 1.
(E and F) HEK293T cells were transfected with the Walk 1 plasmid and constructs expressing either the LIP and the LAP* isoforms in different ratios. Luciferase
activity was normalized to the Renilla luciferase activity and the normalized value of LAP*/LIP-transfected cells (LAP*/LIP ratio = 1) (E) or pcDNA3.1-trasfected
cells (F) was set as 100.
In all panels, data are expressed as mean ± SE of four independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S4.
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Figure 6. miR-142-3p Overexpression Alters Tumor Microenvironment
(A–G)Myeloid infiltrate analysis in the BM, blood, spleen, and tumormass of miR-overexpressing chimeras. FACS analyses were performed on Ly5.2+/mOrange+
cells at day 5 or 10 (except for tumor infiltrate, analyzed only at day 10) following MCA203 injection. Absolute numbers (3106) of granulocytes, monocytes,
macrophages, DCs (CD11c+/I-A/I-E+), and hematopoietic precursors (Sca-1+/c-kit+) are reported.
Data are reported as mean ± SE from n = 6 mice per group, two cumulated experiments. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S5.
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miR-142-3p Regulates M2 Macrophage Differentiationvariation. In particular, this ratio increases as a result of the in-
duction of the LAP* protein, driving macrophage differentiation.
In this scenario, miR-142-3p modulation plays a key role: miR
downregulation, due to the LAP* increase, induces IL6st upregu-
lation, thus sustaining its downstream pathway. Moreover,
miR-142-3p downregulation determines, in a feedback loop,
LAP* expression increment, further promoting myeloid cell dif-
ferentiation towards immunosuppressive macrophages.
miR-142-3p Overexpression Alters Tumor
Microenvironment
We then address whether miR-142-3p overexpression in vivo
could alter tumor microenvironment. We transplanted Ly5.2+
CD11b BM cells infected with a miR-142-3p-coding lentiviral
construct in g-irradiated, Ly5.1+ recipient mice. Infected cells,
identified by the mOrange2 reporter protein, had a constant
miR content, as determined in qRT-PCR (about 1.97 ± 0.261244 Immunity 38, 1236–1249, June 27, 2013 ª2013 Elsevier Inc.compared to control cells). Three weeks after transplantation,
mice were injected with MCA203 tumor cells, and we evaluated
myeloid cell distribution in tumor mass and lymphoid organs at
two different time points (Figure S5A).
At day 5, miR overexpressing mice showed a strong reduction
in macrophage-monocyte subsets, a modest decrease in gran-
ulocytes, but a remarkable drop in the percentage of immature
precursors. Moreover, an increase in BM-DCs was evidenced
(Figure 6A). A similar drive in myeloid maturation was already
reported in Cebpb/ mice (Marigo et al., 2010), further high-
lighting the link between this TF and miR-142-3p.
An analogous scenario was still evident at day 10 in BM,
with the exception of an increase in the precursor numbers
(Figure 6B). Whereas minor differences were found among
circulating and splenic cells at day 5 (Figures 6C–6E), a clear in-
crease in the monocyte percentage and a concomitant signifi-
cant reduction of the macrophage number was evidenced in
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Figure 7. Enforced miR-142-3p Expression Favors Antitumor Immune Response leading to Tumor Growth Control
(A) Schedule for ACT protocol in CTRL or miR-142-3p-expressing chimeras.
(B) Survival analysis of tumor-bearing chimeras. Mantel-Haenszel statistics: LV-CTRL+mTERT CTLs versus LV-miR-142-3p+mTERT CTLs, p = 0.007; LV-miR-
142-3p+mTERT CTLs versus LV-miR-142-3p, p = 0.017; LV-miR-142-3p+mTERT CTLs versus MCA203, p = 0.042. All other comparisons were not significant.
n = 12 LV-CTRL+mTERT CTLs; n = 10 LV-miR-142-3p; n = 8 LV-miR-142-3p+mTERT CTLs and MCA203, two cumulated experiments.
(C) ACT was performed in MCA203 tumor-bearing mice previously transplanted with BM cells expressing either CTRL or miR-142-3p oligo. Tumor growth and
survival analysis are reported. Mice were euthanized when the tumor area reached 200 mm2. Mantel-Haenszel statistics: LV-miR-142-3p+mTERT CTLs versus
MCA203, p = 0.00007; LV-CTRL+mTERT CTLs versus MCA203, p = 0.667; LV-miR-142-3p+mTERT CTLs versus LV-CTRL+mTERT CTLs, p = 0.00001. Data are
reported as mean ± SE from n = 10/12 mice per group.
See also Figure S6.
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(Figures 6D–6F), recapitulating the in vitro block in monocyte-
macrophage transition.
Tumor dimension allowed us to analyze tumor infiltrate only at
the latest time point. We detected a similar decrease in the
percentage of macrophages and an associated expansion of
DC numbers (Figure 6G), suggesting that in vivo miR overex-
pression was able to change the ratio of macrophage: DC to
favor the DC expansion.
Enforced miR-142-3p Expression Favors Antitumor
Immune Response leading to Tumor Growth Control
The macrophage subversion and coincident DC expansion
might create a more favorable microenvironment for antitumorT lymphocyte recruitment and activity. Thus, the preconditioning
of BM cell differentiation by miR-142-3p expression could be
an innovative strategy to improve the efficacy of cancer immu-
notherapy. To address this possibility, we generated stable
miR-142-3p expressing chimeras and subjected them to
adoptive cell therapy (ACT) with mouse telomerase (mTERT)
antigen-specific T lymphocytes (CTLs) (Figure 7A). Six weeks
after BM transplantation, a similar chimerism and BM recon-
stitution between the control and miR-overexpressing mice
were found (Figures S6A and S6B).
After tumor injection, mice survival was monitored. CTRL-
lentivirus chimeras receiving ACT and miR overexpressing-
lentivirus chimeras without ACT died within 55 days after tumor
injection, with a time course indistinguishable from nonchimeric,Immunity 38, 1236–1249, June 27, 2013 ª2013 Elsevier Inc. 1245
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miR-142-3p Regulates M2 Macrophage Differentiationtumor-bearing mice (Figure 7B). In contrast, miR overexpressing
mice receiving ACT showed a prolonged survival, with 50% of
them surviving till the end of the observation period (Figure 7B).
We next addressed the potential therapeutic application of
miR-142-3p overexpression. MCA203 tumor-bearing, Ly5.1+
mice were treated with a low dose of 5-fluoracil to induce a
partial myelodepletion and then injected with syngenic Ly5.2+
BM cells previously transfected with either CTRL or miR-142-
3p oligo (Figure S6C). Two weeks after transplantation, a similar
percentage of Ly5.2+ cells in all mice groups was found
(Table S6D). After adoptive transfer of either mTERT or b-GAL
specific (as T lymphocytes recognizing an irrelevant antigen)
CTLs, mice survival was monitored. We found that the
miR-142-3p expression in conjunction with tumor-specific
CTLs administration was able to delay tumor growth and signif-
icantly increase mice survival (Figure 7C).
DISCUSSION
Starting from the early steps of cancerogenesis, tumor cells
modify surrounding environment to evade host immune
response (Bayne et al., 2012; Pylayeva-Gupta et al., 2012).
Moreover, the recruitment to tumor mass and secondary
lymphoid organs of myeloid cells with immunosuppressive
activity is a prominent feature of tumor progression (Gabrilovich
et al., 2012; Ostrand-Rosenberg et al., 2012; Sica and Bronte,
2007). Immature DCs, macrophages, and MDSCs are expanded
and recruited by tumor- and host-released factors (Gabrilovich
et al., 2012; Sica andMantovani, 2012; Viola et al., 2012). Among
various factors, GM-CSF, IL-6, and M-CSF have been clearly
associated with the induction of immunosuppressive programs
in TIMs (Bayne et al., 2012; Bronte et al., 1999; Hume and
MacDonald, 2012; Marigo et al., 2010; Pylayeva-Gupta et al.,
2012), but the molecular mechanisms underlying the altered
myelopoiesis in cancer remain to be fully elucidated.
During late stages of tumor progression, TAMs acquire a
prevalent M2-like phenotype characterized by low IL-12 and
high IL-10 expression. In contrast to M1-type macrophages,
TAMs have poor antitumoral activity but they rather promote
tissue remodeling and angiogenesis, favoring metastatic
dissemination (Sica and Bronte, 2007; Sica and Mantovani,
2012). However, this dualistic vision is challenged by findings
indicating that different functional states can be present among
TAMs of the same tumor microenvironment (Movahedi et al.,
2010; Torroella-Kouri et al., 2009). In numerous solid cancers,
high presence of tumor-recruited macrophages is tightly corre-
lated to poor prognosis (Qian and Pollard, 2010).
Macrophages are extremely plastic cells, and both epigenetic
changes and noncoding RNAs can contribute to their polariza-
tion. For example, miR-155 can target human IL-13Ra1 subunit,
thus decreasing a set of M2 genes in human macrophages
(Martinez-Nunez et al., 2011). We report here that miR-142-3p
controls the generation of M2-type, immunoregulatory macro-
phages during cancer-promoted myelopoiesis, both in vitro
and in vivo, by conventional binding to 3’ UTR and unconven-
tional binding to CDS of target genes in the IL-6 cytokine-family
signaling cascade. Recent studies addressing miR role as
regulator of myeloid cell differentiation and accumulation
have mainly considered the granulocytic subset of MDSCs1246 Immunity 38, 1236–1249, June 27, 2013 ª2013 Elsevier Inc.(Liu et al., 2011, 2012; Zhang et al., 2011). In particular, miR-
17-5p and miR-20a reduced the expression of STAT3 and
modulated the suppressive activity of granulocytic CD11b+
Ly6G+ cells (Zhang et al., 2011). In another report, high levels
of miR-494 were reported to control the nonimmunological
activity of MDSCs. (Liu et al., 2012).
To identify miR regulating the function and the generation
of tumor-recruited myeloid cells, we characterized their full
‘‘miRNome,’’ following purification of CD11b+ cells from five
different transplantable tumors, in two genetic mouse back-
grounds. The choice of evaluating a broad myeloid population
sharing the CD11b marker was determined by the rationale
that tumors often induce a global alteration in myeloid differenti-
ation, resulting in extensive changes in myeloid cell subset
distribution and multiple blocks in differentiation towards the
myeloid mature stages (Gabrilovich et al., 2012). Isolating and
comparing specific cell subsets might thus not allow to pinpoint
miRs responsible for the altered myeloid differentiation program
and, indeed, our data highlight the enrichments in pathways
related to myeloid differentiation.
Block of macrophage differentiation due to miR-142-3p-
enforced expression impaired tumor growth in vivo, but only
when coupled with the adoptive transfer of tumor-specific
CTLs. These results suggest that miR-142-3p mainly impacts
on the regulation of the immunological activity of TAMs. More-
over, in many tissues, the decreased macrophage number was
associated to increased granulocyte and DC differentiation.
Because DCs and monocytes derive from the same hematopoi-
etic precursor cells, we hypothesize that miR-142-3p upregula-
tion is also necessary to drive myeloid differentiation towards a
full DC maturation, by reducing macrophage generation. In this
regard, it is known that the interplay between IL-6 and M-CSF
can drive macrophage differentiation and/or polarization pre-
venting DC maturation from monocytes. In particular, IL-6 upre-
gulates the expression of a functional MCSF-receptor (M-CSFR)
on monocytes, allowing these cells to utilize the M-CSF pro-
duced in autocrine fashion (Chomarat et al., 2000). Analogously,
IL-6 family cytokines, such as LIF and IL-6, can control TAM
generation and M2-polarization through the M-CSFR pathway.
In the tumor microenvironment, where increased LIF and IL-6
levels are found, monocytes consume M-CSF through an
augmented M-CSFR-dependent internalization, and this event
is linked to the skewing towards M2-type macrophages (Duluc
et al., 2007). Our data indicate that miR-142-3p modulates
macrophage differentiation through the alteration of IL-6 ex-
pression and signaling. Moreover, we demonstrated a double
impact of miR-142-3p on the IL-6 signaling pathway. In fact,
miR-142-3p directly regulated gp130, but, more interestingly, it
also modulated the downstream signaling element, C/EBPb. In
this case, we showed that miR overexpression determined a
prominent reduction of the full-length isoform LAP* by binding
to a noncanonical site located in the CDS.
miR-142-3p activity in the regulation of myeloid differentiation
has been recently addressed (Chen et al., 2008; Wang et al.,
2010). The study of Wang and collaborators reported that
miR-142-3p (and miR-29a) level increased during induced
maturation of both monocytes and granulocytes. Additionally,
miR enforced expression is able to overcome the differentiation
block, which is a specific feature of the AML samples. Thus, the
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ferentiated phase was advocated. However, this study did not
address whether a block in the monocyte-macrophage transi-
tion was consequent to miR-142-3p-enforced expression in
CD34+ cells. In our model, miR-142-3p overexpression did not
induce myeloid differentiation but, on the contrary, impaired
macrophage differentiation. This apparent discrepancy is likely
due to the different models analyzed and to the stimuli used.
In addition, we unveiled a reciprocal C/EBPb-miR-142-3p
interaction and defined a feedback loop, which explains how
this miR is downregulated in TIMs. Intriguingly, this mini-circuit
is regulated by an unanticipated activity of LAP* and LIP iso-
forms. Contrary to the expectations, in fact, we found that
LAP* acted as an inhibitory regulator of miR activity. However,
increasing evidence shows that the ‘‘dogma,’’ which defines
LAP* as an activating and LIP as an inhibitory TF, should be
revised. In fact, LIP can also positively regulate the transcription
of some genes, whereas LAP* can act as an inhibitor of gene
transcription (Luedde et al., 2004).
Thinking about possible therapeutic translation of our findings,
we also validated miR-142-3p expression modulation as adju-
vant in ACT against cancer. Transfer of tumor-antigen-specific
T lymphocytes is a promising anticancer strategy, but it is
mandatory to create an optimal environment to allow T lympho-
cyte recruitment to tumor mass and unleash their full effector
functions. This was previously achieved by the conditional ge-
netic ablation of Cebpb gene (Marigo et al., 2010), a strategy
that is difficult to transfer to the clinic given the pleiotropic activity
of this TF. We demonstrated here that the use of an oligo to
enforce miR-142-3p expression could be a feasible option to
modify tumor environment and favor antitumor immunity. We
are currently exploring the possibility to target miR-142-3p to
myeloid cells by the use of nanoparticles and dendrimers.
EXPERIMENTAL PROCEDURES
General Note
All mice were maintained under SPF conditions in the animal facility of the
Istituto Oncologico Veneto, and experiments were performed according to
state guidelines and approved by the local ethics committee. C57BL/6 and
BALB/c mice were purchased from Harlan (Milan, Italy). Transgenic mice
and tumor cell lines were described in the Supplemental Information.
Mouse recombinant GM-CSF, G-CSF, IL-6, and M-CSF were purchased
from Peprotech. Db-restricted hgp10025–33 were synthesized by JPT (Berlin,
Germany).
Cell Isolation
CD11b+ and CD11b cells were isolated by using magnetic microbeads con-
jugated with monoclonal rat anti-mouse-human CD11b antibody. Separations
were performed by Miltenyi Biotec kits and MidiMacs LS or LD columns,
respectively (Miltenyi Biotec, Germany).
Flow Cytometry
Antibodies, described in Supplemental Information, and matched isotypes
were purchased from eBiosciences. Fluorescence acquisition was performed
with FACSCaliburTM (Becton and Dickinson) and analyzed with FlowJo
software (Treestar).
Bone Marrow Cultures
BMcells were obtained as previously described (Marigo et al., 2010). To obtain
BM-MDSCs, we plated 1.2 3 106 cells into 6-well plates in medium supple-
mented with either cytokines or 25% v/v TCCM and maintained at 37C in a5% CO2-humidified atmosphere for 4 days. TCCM was obtained by culturing
subconfluent tumor cells in medium with 3% serum for 48 hr. Supernatants
were then collected, aliquoted, and kept at 80C until use.
BM Transfection
Fresh BM cells were transfected with either 100 nM of miR-142-3p mimic
or scramble CTRL oligo (IDT), by using the transfection agent GeneSilencer
(Genlantis) according to manufacturer’s instructions. After 5 hours, cytokines
or TCCM were added.
In Vitro CFDA-SE Labeling and Proliferation Assay
Mixed-leukocyte peptide cultures (MLPC) were set up as described in Supple-
mental Information.
qRT-PCR
Total RNA was extracted from cells by using Trizol reagent (Life Technologies).
Taqman probes were used for the detection of miRs (Applied Biosystems), as
described by the manufacturer, by using small nuclear RNA sno292 as endog-
enous control. For mRNA-level analysis, cDNA was generated by using
reverse transcriptase SuperScript II and poly dT primers (Invitrogen). Real-
time PCR was performed by using SYBR Green Master Mix (Invitrogen) and
the ABI 7900HT fast real-time PCR System (Applied Biosystems). Primers
are described in the Supplemental Information. S18 was used as endogenous
control. Relative quantification of miRNA and mRNA expression was per-
formed by using the DDCT method.
Enzyme-Linked Immunosorbent Assay
ELISA for murine IL-12p70 and IL-10 was performed with R&D kits, following
manufacturer’s instructions.
Immunoblot Analysis
Nuclear cell extracts were obtained from 3 3 106 cells by using the Pierce
NE-PER nuclear reagents (Pierce Biotechnology) in presence of protease in-
hibitors (Calbiochem). The following antibodies were used: C/EBPb (1:1,000,
Santa Cruz), gp130 (1:1,000, eBiosciences), p-STAT-3 Tyr705 (1:1,000, Cell
Signaling), STAT3 (1:1,000, Santa Cruz), Nucleoporin p62 (1:1,000, BD), and
a-Actin (1:5,000, Sigma). Secondary HRP-conjugated Abs were obtained
from GE Healthcare Life Sciences. Immunoblots were analyzed by ECL
(Pierce Biotecnology). Signal quantification was performed by using ImageJ
Software.
Transduction of Hematopoietic Progenitor-Enriched CD11b– Cells
and Transplantation Procedure
We transduced 33 106 BM-CD11b cells with mock, miR-142-3p expressing
or miR-142-3p sponge lentiviral vector stocks, produced as described in
Supplemental Information, at a multiplicity of infection (MOI) of 75 for 18
hour. For in vitro experiments, CD11b-transduced cells were cultured in
G-CSF-containing medium for 4 days. Transduction of CD11b and stable
chimera generation were obtained as previously described (Montini et al.,
2006).
Adoptive T Cell Transfer Protocol
Eight weeks after transplantation, chimera mice were injected s.c. with
MCA203 fibrosarcoma cells and ACT was performed as previously described
(Ugel et al., 2010).
Luciferase Reporter Assay
HEK293T cells were cultured to 80% confluence in 24-well plates and trans-
fected as described in Supplemental Information.
Statistics
All results are expressed asmean ± SE. Student’s t test was used to determine
p values. Kaplan-Meier survival analysis was performed for the comparison
of survival curves. Statistical significance was defined as p < 0.05. In figures,
asterisks were used as follows: * p%0.05; ** p%0.01; *** p%0.001.Immunity 38, 1236–1249, June 27, 2013 ª2013 Elsevier Inc. 1247
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